{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"6.800","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"111,468,814","primaryexch":"香港交易所","ric":"2496.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"M","am_u":"K","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0,"inline_upper_strike_price":"","sedol":"BNNMZ08","am":"72.53","iv":"","ew_strike":"","as":"6.980","geographic_focus":null,"incorpin":"中華人民共和國","etp_baseCur":null,"ew_amt_os":"","bd":"5.320","registrar":"香港中央證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"200","update_time":"2025-09-28 00:06:03.0","lo52":"3.650","shares_issued_date":"2025年8月31日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"K","base_currency":null,"coupon":"","expiry_date":"","chairman":"Zhou Pengfei","underlying_ric":"2496.HK","hi52":"8.280","issuer_name":"武漢友芝友生物製藥股份有限公司 - B - H股","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日13:55","aum_date":"","lo":"6.300","mkt_cap":"757.98","f_aum_hkd":null,"ew_sub_per_to":"","ls":"6.800","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"+0.500","aum":"","issued_shares_class_B":null,"vo":"11.00","secondary_listing_flag":false,"listing_date":"2023年9月25日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"武漢友芝友生物製藥股份有限公司 - B - H股","nm_s":"友芝友生物－Ｂ","sym":"2496","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"武漢友芝友生物製藥股份有限公司是一家主要從事發現、開發及商業化抗腫瘤雙特異性抗體方面的新型創新藥物的中國公司。該公司致力於開發用於治療癌症相關併發症、癌症及老年性眼科疾病的基於雙特異性抗體(BsAb)療法，以解決腫瘤學及老年眼科病領域的醫療需求。該公司的核心產品M701是一種靶向人癌細胞表面抗原EpCAM和人T細胞表面抗原CD3的重組BsAb。該公司的產品管線還包括Y101D、Y332、Y225等。","op":"6.300","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"中國湖北省武漢市<br/>東湖新技術開發區<br/>高新大道666號","pc":"+7.94","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"6.300","isin":"CNE1000063C4","moneyness":""}},"qid":"1759075073284"}
